US0403341045 - Common Stock
ARIDIS PHARMACEUTICALS INC
NASDAQ:ARDS (7/18/2023, 7:14:23 PM)
After market: 0.2619 -0.05 (-15.54%)0.3101
+0.05 (+17.91%)
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company is headquartered in Los Gatos, California and currently employs 37 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The firm's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
ARIDIS PHARMACEUTICALS INC
983 University Avenue, Bldg. B
Los Gatos CALIFORNIA 95032
P: 14083851742.0
CEO: Vu Truong
Employees: 37
Website: https://aridispharma.com
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery...
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS,...
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and...
It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning.
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European...
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Here you can normally see the latest stock twits on ARDS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: